Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.

Gou H, Zhai Y, Guo J

European journal of pediatrics6 Sept 2023Cited by 8 (Europe PMC)

PMID37672063DOI10.1007/s00431-023-05186-8PepBankPUB-37672063

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide use was associated with reduced body weight.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide was linked to lower body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight (WMD)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−2.13 kg
body weight
Source sentences
Summary
Liraglutide use was associated with reduced body weight (WMD: -2.13 kg; 95%CI: -4.23, -0.03)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206301
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide use was associated with reduced BMI.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide was linked to lower BMI.
Peptide
Liraglutide
Outcome
DecreaseBMI (WMD)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−1.56 kg/m2
BMI
Source sentences
Summary
BMI (WMD: -1.56 kg/m²; 95% CI: -2.41, -0.7)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206302
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide use was associated with reduced BMI SDS.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide was linked to a lower BMI score adjusted for age and sex.
Peptide
Liraglutide
Outcome
DecreaseBMI SDS (WMD)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−0.17 SDS
BMI SDS
Source sentences
Summary
BMI SDS (WMD: -0.17; 95% CI: -0.26, -0.08)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206303
04HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide use was associated with reduced HbA1c.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide was linked to lower HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c (WMD)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−0.29%
HbA1c
Source sentences
Summary
Similar associations were found in HbA1c (WMD: -0.29%; 95% CI: -0.52, -0.06)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206304
05HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide use was associated with reduced fasting plasma glucose.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide was linked to lower fasting blood glucose.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose (SMD)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.39 SMD
fasting plasma glucose
Source sentences
Summary
and fasting plasma glucose (SMD: -0.39; 95% CI: -0.64, -0.14)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206305
06HumanSystematic reviewEfficacy outcome
In a subgroup analysis of children with type 2 diabetes, liraglutide improved HbA1c control; no such improvement was seen in the other children.
In plain wordsIn a pooled analysis, liraglutide lowered HbA1c only in children with type 2 diabetes.
Peptide
Liraglutide
Outcome
DecreaseHbA1c in children with type 2 diabetes (subgroup)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
WMD
−1.06%
HbA1c, children with type 2 diabetes
Source sentences
Summary
Subgroup analysis shows an improvement in HbA1c control only among children with type 2 diabetes (WMD: -1.06%; 95% CI: -1.44, -0.67).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206306
07HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in fasting serum insulin.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change fasting insulin compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeFasting serum insulin
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206307
08HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in systolic blood pressure.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change systolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206308
09HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in diastolic blood pressure.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change diastolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeDiastolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206309
10HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in HDL.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change HDL cholesterol compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeHDL cholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206310
11HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in LDL.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change LDL cholesterol compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeLDL cholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206311
12HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in children and adolescents, liraglutide did not differ from placebo in TG.
In plain wordsIn a pooled analysis of trials in children and teenagers, liraglutide did not change triglycerides compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeTriglycerides
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
No differences were found in fasting serum insulin, SBP, DBP, HDL, LDL, and TG between liraglutide and placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206312
13HumanSystematic reviewSafety outcome
In a meta-analysis of RCTs in children and adolescents, the frequency of adverse events did not differ between liraglutide and placebo.
In plain wordsIn a pooled analysis of trials in children and teenagers, side effects were no more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
No significant changeFrequency of adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
In addition, no difference was found in the frequencies of adverse events, serious adverse events, and adverse events resulting in discontinuation of therapy between liraglutide and placebo treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206313
14HumanSystematic reviewSafety outcome
In a meta-analysis of RCTs in children and adolescents, the frequency of serious adverse events did not differ between liraglutide and placebo.
In plain wordsIn a pooled analysis of trials in children and teenagers, serious side effects were no more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
No significant changeFrequency of serious adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
In addition, no difference was found in the frequencies of adverse events, serious adverse events, and adverse events resulting in discontinuation of therapy between liraglutide and placebo treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206314
15HumanSystematic reviewSafety outcome
In a meta-analysis of RCTs in children and adolescents, adverse events resulting in discontinuation did not differ between liraglutide and placebo.
In plain wordsIn a pooled analysis of trials in children and teenagers, stopping treatment because of side effects was no more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
No significant changeAdverse events resulting in discontinuation
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
In addition, no difference was found in the frequencies of adverse events, serious adverse events, and adverse events resulting in discontinuation of therapy between liraglutide and placebo treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) evaluating the effects of liraglutide in children and youth were included.
Summary · context
Seven eligible articles were finally included, covering a population of 547 participants.
Report a problemFND-3767206315

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.